why take bpc 157 What is BPC-157? BPC-157 10mg - Wellness Clinic

It was placed on the FDAs 503A Category 2 bulk-substances list in September 2023, a designation that restricted its use in pharmacy compounding

IGF-1 LR3 Reconstitution Reference (1 mg / 1,000 mcg vial) BAC water added 1 mL Concentration 1,000 mcg/mL 20 mcg dose 0.02 mL (2 units) 40 mcg dose 0.04 mL (4 units) 50 mcg dose 0.05 mL (5 units) 80 mcg dose 0.08 mL (8 units) 100 mcg dose 0.10 mL (10 units) BAC water added 2 mL Concentration 500 mcg/mL 20 mcg dose 0.04 mL (4 units) 40 mcg dose 0.08 mL (8 units) 50 mcg dose 0.10 mL (10 units) 80 mcg dose 0.16 mL (16 units) 100 mcg dose 0.20 mL (20 units) BAC water added 3 mL Concentration 333 mcg/mL 20 mcg dose 0.06 mL (6 units) 40 mcg dose 0.12 mL (12 units) 50 mcg dose 0.15 mL (15 units) 80 mcg dose 0.24 mL (24 units) 100 mcg dose 0.30 mL (30 units) Units refer to U-100 insulin syringe markings

Were experts in using B12 for the flu, colds, other illnesses and general immune system support

Long arginine 3-IGF-1, abbreviated as IGF-1 LR3 or LR3-IGF-1, is a synthetic protein and lengthened analogue of human insulin-like growth factor 1 (IGF-1).[1][2] It differs from native IGF-1 in that it possesses an arginine instead of a glutamic acid at the third position in its amino acid sequence (arginine 3), and also has an additional 13 amino acids at its N-terminus (MFPAMPLLSLFVN) (long), for a total of 83 amino acids (relative to the 70 of IGF-1).[2] The consequences of these modifications are that IGF-1 LR3 retains the pharmacological activity of IGF-1 as an agonist of the IGF-1 receptor, has very low affinity for the insulin-like growth factor-binding proteins (IGFBPs), and has improved metabolic stability.[1][2] As a result, it is approximately three times more potent than IGF-1,[3] and possesses a significantly longer half-life of about 2030 hours (relative to IGF-1s half-life of about 1215 hours).[4] IGF-1 LR3 Peptide is under active investigation in a number of cell culture and animal models